Aktieanalyser från populära analyshus

26 Feb 07:19

Elicera Therapeutics: Secures warrant program through a combination of guarantees and subscription commitments - Redeye

Elicera Therapeutics

26 Feb 07:19

Analyst Group kommenterar EcoRubs Q4-rapport

EcoRub publicerade den 24 februari 2025 bolagets delårsrapport för det fjärde kvartalet år 2024.

EcoRub

25 Feb 15:12

Titania: Omotiverat hög substansrabatt medför attraktiv risk-reward - Analyst Group

Titania

Analys | Analysguiden

25 Feb 15:11

Systemair: Tredje kvartalet 2024/25 - Analysguiden

Systemair förväntas redovisa en försäljning på 2 899 MSEK för tredje kvartalet, en ökning med 2,7% j...

Systemair

Analys | Analysguiden

25 Feb 15:11

Cantargia: På väg mot licensaffär - Analysguiden

Infracom: Rapportkommentar Q4’24 - Kalqyl

Nettoomsättningen uppgick till 231,2 MSEK (219,5), vilket motsvarade en ökning med 5,3 procent y-o-y...

Infracom

25 Feb 11:45

Zoomability: Stärkt position för att accelerera under år 2025 - Analyst Group

Lipum: Positive top-line results - Redeye

Redeye leaves a comment following Lipum’s announcement of positive top-line results from the phase I...

Oncopeptides: Real World Data Support Pepaxti - Redeye

BONESUPPORT Q4: Initial take – slight miss on sales, big beat on EBIT - Redeye

Redeye notes yet another strong quarter with a doubling of US CERAMENT G sales, a solid EBIT and a s...

Scibase Q4’24: Strong growth in the US - Redeye

Kancera Q4: Active in 2025, FRACTIVE in 2026 - Redeye

Redeye returns following Kancera's Q4 report. We note that 2025 is shaping up to be a pivotal year, ...

Suominen: Waiting for steeper recovery - Evli

Xoma: Rapportkommentar Q4’24 - Kalqyl

FLOW väcker redan stort intresse Xoma har på kort tid inlett tre testprojekt med svenska företag ino...

TH1NG: Placed Under Review - Redeye

TH1NG

24 Feb 15:53

Analyst Group kommenterar Refine Groups Q4-rapport 2024

Refine Group publicerade den 24 februari 2025 bolagets delårsrapport för det fjärde kvartalet år 202...

Refine Group

24 Feb 14:47

Ovzon: Positive EBITDA and FCF, strong backlog - ABG

CoinShares: No exposure to the Bybit exchange - Redeye

On 21 February, hackers stole about USD1.5bn in crypto assets from Bybit, a Dubai-based crypto excha...

Angler Gaming: Rapportkommentar Q4’24 - Kalqyl

Angler Gaming

24 Feb 13:18

Energy Save: Expect a gradual recovery - ABG

Q4 sales +25% y-o-y, +4% q-o-q, FCF positive We expect new OEM partnerships to ramp up towards end '...

Absolent: Reorganized for higher growth - Redeye

Absolent Air Care

24 Feb 12:16

StrongPoint: Markets remain muted - ABG

Q4 largely in line, Q1 likely flat Contracts developing slowly - lower target range likely Weak '24 ...

StrongPoint

24 Feb 12:14

Analyst Group kommenterar AcuCorts Q4-rapport

Cantargia Q4 2024: Focus on Business Development - Redeye

Redeye comments on Cantargia's Q4 report. The company faces a major catalyst in the first placebo-co...

Angler Gaming, kv4 2024: Utdelning återupptas, men tillväxten saknas - Carlsquare

Freemelt: Rights issue outcome - Redeye

Redeye comments on the outcome of Freemelt’s rights issue.

Active Biotech: First Patient Recruited in Myelofibrosis - Redeye

Active Biotech

24 Feb 09:03

DistIT: Progress across all segments - ABG

'25e-'26e EBIT up 6-15% Return to organic growth likely in Q2'25 '25e-'26e EV/EBIT of 14x-6x Starti...

DistIT